Literature DB >> 6271318

Sympathetic mechanisms in diet-induced thermogenesis: modification by ciclazindol and anorectic drugs.

N J Rothwell, M J Stock, M G Wyllie.   

Abstract

1 The sympathetic noradrenergic activation of brown adipose tissue and the biochemical mechanisms involved in diet-induced thermogenesis were studied in rats. 2 A close correlation was found between brown adipose tissue Na+, K+-adenosinetriphosphatase (Na+, K+-ATPase) activity in vitro and in vivo measurements of resting oxygen consumption (VO2). The effects of noradrenaline on in vitro NA+, K+-ATPase activity in brown adipose tissue and in vivo VO2 could be mimicked by a variety of agents. These included beta-adrenoceptor agonists and agents known to induce the release of noradrenaline or inhibit the noradrenaline uptake process. The pharmacological evidence suggests that dopaminergic mechanisms may also be involved in the control of thermogenesis. 3 Amphetamine did not increase VO2 in rats without causing associated increases in locomotor activity. Ciclazindol at doses of 3-30 mg/kg intraperitoneally increased VO2 but did not appear to increase locomotor activity or evoke any other signs of CNS stimulation including lengthening of time to sleep onset or stereotypy. Separation of metabolic and CNS effects occurred only at the lowest dose of mazindol used (0.3 mg/kg i.p.). These results are probably a reflection of (a) the relative abilities of these drugs to inhibit brain and brown adipose noradrenaline uptake processes and (b) the relatively high accumulation of ciclazindol in brown adipose. 4 Of the drugs tested, only ciclazindol was a more potent inhibitor of the noradrenaline uptake system in brown adipose tissue (BAT) than in brain. Kinetic analysis also revealed that the actions of ciclazindol on the NA uptake system and Na+, K+-ATPase in BAT differed from those of mazindol. 5 These findings suggest that ciclazindol may produce an energy wasting effect in rodents without causing overt CNS stimulation; the implications of these findings in terms of human obesity are discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6271318      PMCID: PMC2071762          DOI: 10.1111/j.1476-5381.1981.tb10462.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

1.  Effects of prostaglandins on the ATPase activities of synaptosomes.

Authors:  J C Gilbert; M G Wyllie
Journal:  Biochem Pharmacol       Date:  1975-02-15       Impact factor: 5.858

2.  An automatic, closed-circuit oxygen consumption apparatus for small animals.

Authors:  M J Stock
Journal:  J Appl Physiol       Date:  1975-11       Impact factor: 3.531

3.  Pharmacokinetic studies on WY 23409 HCl.

Authors:  A J Swaisland; R A Franklin; R J Southgate
Journal:  Br J Clin Pharmacol       Date:  1975-10       Impact factor: 4.335

Review 4.  Cellular thermogenesis.

Authors:  J Himms-Hagen
Journal:  Annu Rev Physiol       Date:  1976       Impact factor: 19.318

5.  The effect of adrenergic agonists and cyclic AMP on the Na+/K+ ATPase activity of brown adipose tissue.

Authors:  B A Horwitz; M Eaton
Journal:  Eur J Pharmacol       Date:  1975-11       Impact factor: 4.432

Review 6.  Catecholamine-sensitive adenylate cyclases in nervous tissues.

Authors:  L L Iversen
Journal:  J Neurochem       Date:  1977-07       Impact factor: 5.372

7.  Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor".

Authors:  J W Kebabian; G L Petzold; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1972-08       Impact factor: 11.205

8.  Na+, K+-ATPase activity and noradrenaline turnover in brown adipose tissue of rats exhibiting diet-induced thermogenesis.

Authors:  N J Rothwell; M J Stock; M G Wyllie
Journal:  Biochem Pharmacol       Date:  1981-06-15       Impact factor: 5.858

9.  The action of indoramin and other compounds on the uptake of neurotransmitters into rat cortical slices.

Authors:  R F Sugden
Journal:  Br J Pharmacol       Date:  1974-07       Impact factor: 8.739

10.  Some effects of mazindol, an anorectic drug, on rat brain monoaminergic systems.

Authors:  M F Sugrue; G Shaw; K G Charlton
Journal:  Eur J Pharmacol       Date:  1977-04-21       Impact factor: 4.432

View more
  3 in total

Review 1.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  The involvement of potassium channels in the action of ciclazindol in rat portal vein.

Authors:  T Noack; G Edwards; P Deitmer; P Greengrass; T Morita; P O Andersson; D Criddle; M G Wyllie; A H Weston
Journal:  Br J Pharmacol       Date:  1992-05       Impact factor: 8.739

3.  Ciclazindol: an oral agent with weight reducing properties and hypoglycaemic activity.

Authors:  M E Lean; L J Borthwick
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.